The effect of ozone therapy on chemotherapy-induced neuropathy

The effect of ozone therapy on chemotherapy-induced neuropathy in cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221219056871N2

Enrollment

Registered

2025-07-23

Start date

2025-08-22

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced neuropathy. Polyneuropathy in neoplastic disease

Interventions

Intervention 1: Intervention group: In addition to duloxetine (which is the standard treatment), patients undergo ozone therapy at a dose of 30 every 12 hours in the following manner: Major hemotherap

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients who have developed chemotherapy-induced neuropathy following at least one month of chemotherapy patients expected life span more than 6 months

Exclusion criteria

Exclusion criteria: Patients who have neuropathy for any reason before starting chemotherapy (diabetes, autoimmune diseases). Patients with favism Patients with Hemoglobinopathies Patients with coagulation disorder Patients with platelet less than 40000

Design outcomes

Primary

Measure	Time frame
Examination score of diapason before and after intervention in two ozone therapy and control groups. Timepoint: At the beginning of the study and then every ten sessions of ozone therapy. Method of measurement: Grading based on the correct answers of patients in the standard examination of neuropathy with diapason.;Quality of life questionnaire scores of patients before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Quality of life questionnaire score based on QLC30 and Iranian society culture.;Findings of the nerve and muscle bands before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Performing a nerve and muscle strip test.;Examination score with monofilaman before and after the intervention in two ozone therapy and control groups. Timepoint: At the beginning of the patient's arrival in study and then every 10 sessions until the end of the study. Method of measurement: Grading based on standard clinical examination with monofilament.	—

Measure

Time frame

Examination score of diapason before and after intervention in two ozone therapy and control groups. Timepoint: At the beginning of the study and then every ten sessions of ozone therapy. Method of measurement: Grading based on the correct answers of patients in the standard examination of neuropathy with diapason.;Quality of life questionnaire scores of patients before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Quality of life questionnaire score based on QLC30 and Iranian society culture.;Findings of the nerve and muscle bands before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Performing a nerve and muscle strip test.;Examination score with monofilaman before and after the intervention in two ozone therapy and control groups. Timepoint: At the beginning of the patient's arrival in study and then every 10 sessions until the end of the study. Method of measurement: Grading based on standard clinical examination with monofilament.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Izadi

Bagheiat-allah University of Medical Sciences

morteza_izadi@yahoo.com+98 21 8805 0435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026